Tinavi

Tinavi Medical Technologies stands as China’s pioneer in orthopedic surgical robotics, having developed from a 2004 research collaboration between Beijing Jishuitan Hospital and Beihang University into the country’s first company to commercialize domestically developed orthopedic surgical robots.

Company Overview

Established in 2005, Tinavi emerged from the technology transfer of an orthopedic surgical robot project jointly undertaken by Beijing Jishuitan Hospital and Beijing University of Aeronautics and Astronautics. The company became China’s first and the world’s fifth enterprise to obtain a Class III medical device registration certificate for orthopedic surgical robots.

In July 2020, Tinavi successfully listed on the Shanghai Stock Exchange’s STAR Market under the ticker 688277.SH, becoming the first publicly traded orthopedic surgical robot company in China. The IPO raised approximately CNY 452 million, providing capital for continued R&D expansion and market penetration.

The company has accumulated over 300 patents and received the Second Prize of China’s National Science and Technology Progress Award in 2015. Tinavi serves as the supporting unit for the National and Local Joint Engineering Research Center of Medical Robots and maintains a postdoctoral research workstation.

Core Products

TiRobot II (Tianji 2.0)

The second-generation orthopedic surgical robot system, approved by NMPA in 2021, serves as Tinavi’s primary commercial product. TiRobot II covers full-segment spinal surgery (cervical, thoracic, lumbar, and sacral vertebrae) and trauma surgery (pelvis, acetabulum, and extremities). The system received CE MDR certification in August 2024 for its spinal function module and CSA certification for the North American market.

TiRobot Recon (Tianji Joint)

Expanding into the joint replacement segment, TiRobot Recon received NMPA approval for total knee arthroplasty (TKA) in 2023, followed by approval for total hip arthroplasty (THA) in 2024. The system features intelligent planning, dynamic balancing, free osteotomy, and smooth tracking capabilities designed specifically for joint replacement procedures.

TiRobot Sirui (Tianji Sirui)

Approved in 2025, TiRobot Sirui represents Tinavi’s latest full-spectrum orthopedic platform supporting intelligent decision-making across spine, trauma, and joint procedures. The system reportedly improves surgical efficiency by 30% while reducing intraoperative radiation exposure by 70%.

Technology & Innovation

Tinavi’s TiRobot platform is described as the world’s only orthopedic surgical robot system capable of performing surgeries across spine, trauma, and joint replacement on a single device. This “one machine, three applications” approach differentiates it from competitors that typically require separate systems for each surgical category.

Core technologies include:

• Robotic arm configuration technology with high-precision online calibration
• AI-powered medical image processing and automatic surgical planning
• Active-passive hybrid optical tracking system
• 2D and 3D imaging compatibility with C-arm integration

The company invested CNY 122 million in R&D in 2022, representing 78.52% of total revenue, demonstrating sustained commitment to technological advancement despite commercial pressures.

Market Presence

As of Q1 2025, Tinavi’s orthopedic surgical robots have been deployed in over 200 medical institutions across all 31 provinces, autonomous regions, and directly-administered municipalities in China. The cumulative surgical case count exceeded 120,000 by June 2025, with over 22,000 procedures performed in H1 2025 alone.

In the trauma orthopedics segment, Tinavi holds a dominant 97.3% market share among domestic competitors. The 2023 fiscal year saw over 24,000 robot-assisted surgeries, representing nearly 90% year-over-year growth.

Internationally, Tinavi has obtained CE MDR certification (August 2024) for European market access and CSA certification for North American markets, though FDA clearance has not yet been achieved.

Key Milestones

• 2005: Company founded based on Jishuitan Hospital and Beihang University research
• 2016: TiRobot (Tianji 1.0) receives NMPA Class III medical device approval
• 2018: Exhibited at China International Import Expo alongside high-speed rail and C919 aircraft
• 2020: IPO on Shanghai STAR Market (688277.SH)
• 2021: TiRobot II (Tianji 2.0) receives NMPA approval
• 2023: TiRobot Recon approved for total knee arthroplasty
• 2024: CE MDR certification obtained; THA indication added to TiRobot Recon
• 2025: TiRobot Sirui full orthopedic platform approved; cumulative surgeries exceed 120,000

Frequently Asked Questions

What surgical procedures can Tinavi robots perform?

Tinavi’s TiRobot platform covers three major orthopedic categories: spine surgery (cervical through sacral segments), trauma surgery (pelvis, acetabulum, extremities), and joint replacement (total knee and total hip arthroplasty). It is positioned as the only orthopedic robot globally capable of addressing all three categories on a single system.

Is Tinavi publicly traded?

Yes, Tinavi trades on the Shanghai Stock Exchange’s STAR Market under ticker 688277.SH since July 2020. It was the first orthopedic surgical robot company to go public in China.

Does Tinavi have FDA approval?

As of January 2026, Tinavi has not received FDA 510(k) clearance for the US market. The company has obtained CE MDR certification for Europe (2024) and CSA certification for North America (Canada), with international expansion ongoing.

How many surgeries have been performed with TiRobot?

By June 2025, Tinavi reported cumulative surgical cases exceeding 120,000 across more than 200 medical institutions in China.